Evaluate the Safety and Immunogenicity After MG1111 as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st SUDUVAX Inj. Vaccination

Condition:   Varicella Interventions:   Biological: MG1111 (BARICELA);   Biological: VARIVAX;   Biological: Suduvax Sponsor:   Green Cross Corporation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials